Intercept Pharmaceuticals, Inc. (ICPT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Intercept Pharmaceuticals, Inc. (ICPT) trades at $19.00 with AI Score 51/100 (Grade B). Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for progressive non-viral liver diseases. Market cap: $794.69M, Sector: Healthcare.
Price live · AI analysis from May 6, 2026Analyst Coverage for ICPT: ICPT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ICPT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ICPT: the 7 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Intercept Pharmaceuticals, Inc. (ICPT) Healthcare & Pipeline Overview
Intercept Pharmaceuticals, Inc. develops and commercializes therapeutics for progressive non-viral liver diseases, focusing on its primary product, Ocaliva, used in treating primary biliary cholangitis. The company operates in the biotechnology sector, addressing unmet needs in liver disease treatment across the United States, Europe, and Canada.
What Is the Investment Thesis for ICPT?
Intercept Pharmaceuticals presents a focused investment opportunity within the biopharmaceutical sector, driven by its established product, Ocaliva, and its potential in addressing NASH. Ocaliva's revenue stream from PBC treatment, coupled with a gross margin of 99.7%, provides a solid financial foundation. The company's ongoing development of Ocaliva for NASH represents a significant growth catalyst, targeting a large and underserved patient population. Intercept's P/E ratio of 5.6 suggests a potentially undervalued stock relative to its earnings. However, investors may want to evaluate the risks associated with clinical trial outcomes and regulatory approvals for NASH, as well as competition from other companies developing NASH therapies. The company's beta of 0.88 indicates lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
ICPT Key Highlights
- Market Cap of $794.69M reflects Intercept's current valuation in the biopharmaceutical market.
- P/E Ratio of 5.6 suggests the company is potentially undervalued compared to its earnings.
- Profit Margin of 40.3% indicates strong profitability in its operations.
- Gross Margin of 99.7% highlights the efficiency of Intercept's production and sales processes.
- Beta of 0.88 suggests lower volatility compared to the overall market, indicating a relatively stable investment.
Who Are ICPT's Competitors?
ICPT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| ABBV AbbVie Inc. | $255.67 | -2.07% | $451.72B | 78 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ICPT's Key Strengths?
- Established product (Ocaliva) with regulatory approval for PBC.
- Strong gross margin (99.7%).
- Focus on a specialized area of liver diseases.
- Experienced management team.
What Are ICPT's Weaknesses?
- Reliance on a single product (Ocaliva) for revenue.
- Potential competition from other companies developing NASH therapies.
- Regulatory risks associated with drug development and approval.
- Limited geographic presence compared to larger pharmaceutical companies.
What Could Drive ICPT Stock Higher?
- Potential regulatory approval of Ocaliva for NASH, which could significantly expand the company's market opportunity.
- Continued growth in Ocaliva sales for PBC treatment.
- Progress in clinical trials for other liver disease indications.
- Potential strategic partnerships or acquisitions to expand the product portfolio.
What Are the Key Risks for ICPT?
- Financial-distress signal — its Altman Z-Score of -4.96 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for NASH, which could negatively impact the company's growth prospects.
- Regulatory setbacks or delays in obtaining approval for new therapies.
- Competition from other companies developing treatments for liver diseases.
- Changes in healthcare policies or reimbursement rates that could affect Ocaliva sales.
- Patent expiration for Ocaliva
What Are the Growth Opportunities for ICPT?
- Expansion into NASH Market: Nonalcoholic steatohepatitis (NASH) represents a substantial growth opportunity for Intercept. The NASH market is projected to reach billions of dollars in the coming years, driven by the increasing prevalence of obesity and diabetes. Intercept is developing Ocaliva for the treatment of NASH, and positive clinical trial results and regulatory approval could significantly boost the company's revenue. The timeline for potential approval is dependent on ongoing clinical trials, with potential market entry within the next 2-3 years.
- Geographic Expansion: Intercept currently markets Ocaliva in the United States, Europe, and Canada. Expanding into new geographic markets, particularly in Asia and Latin America, could drive additional growth. These regions have a growing prevalence of liver diseases and an increasing demand for advanced therapies. The timeline for geographic expansion will depend on regulatory approvals and market access strategies in each region, with potential entry into new markets within the next 3-5 years.
- Pipeline Development: Intercept has a pipeline of other product candidates in various stages of clinical and preclinical development. Advancing these product candidates through clinical trials and obtaining regulatory approval could diversify the company's revenue streams and reduce its reliance on Ocaliva. These pipeline programs target different mechanisms of action to address a range of liver diseases, offering potential for future growth and innovation. Clinical trial timelines vary, but potential new product launches could occur within the next 5-7 years.
- Strategic Partnerships and Acquisitions: Intercept could pursue strategic partnerships or acquisitions to expand its product portfolio, access new technologies, or enter new markets. Collaborating with other companies in the biotechnology or pharmaceutical industry could accelerate the development and commercialization of new therapies. Potential acquisition targets could include companies with complementary technologies or products in the liver disease space. The timeline for potential partnerships or acquisitions is uncertain, but such deals could significantly impact the company's growth trajectory.
- Lifecycle Management of Ocaliva: Intercept can extend the lifecycle of Ocaliva through various strategies, such as developing new formulations, exploring new indications, or conducting post-marketing studies to demonstrate additional benefits. These efforts can help maintain Ocaliva's market share and revenue stream in the face of potential competition from generic or biosimilar products. The timeline for lifecycle management initiatives is ongoing, with continuous efforts to optimize Ocaliva's value proposition and market position.
What Opportunities Does ICPT Have?
- Expansion into the NASH market.
- Geographic expansion into new regions.
- Development of new therapies for other liver diseases.
- Strategic partnerships and acquisitions.
What Threats Does ICPT Face?
- Unfavorable clinical trial results for NASH.
- Regulatory setbacks or delays.
- Generic or biosimilar competition for Ocaliva.
- Changes in healthcare policies or reimbursement rates.
What Are ICPT's Competitive Advantages?
- Proprietary drug formulations (e.g., Ocaliva).
- Patent protection for its products and technologies.
- Regulatory exclusivity for Ocaliva in the treatment of PBC.
- Clinical data supporting the efficacy and safety of its therapies.
What Does ICPT Do?
Intercept Pharmaceuticals, Inc., founded in 2002 and headquartered in New York City, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for progressive non-viral liver diseases. The company's lead product, Ocaliva (obeticholic acid), is a farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Ocaliva represents a significant advancement in the treatment of PBC, a chronic liver disease. Intercept is also actively investigating Ocaliva for other liver diseases, including nonalcoholic steatohepatitis (NASH), a prevalent and progressive liver condition with limited treatment options. Beyond Ocaliva, Intercept has a pipeline of other product candidates in various stages of clinical and preclinical development, targeting different mechanisms of action to address a range of liver diseases. The company markets its products through its own commercial organization and through third-party distributors, primarily in the United States, Europe, and Canada. Intercept also has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States.
What Products and Services Does ICPT Offer?
- Develop and commercialize therapeutics for progressive non-viral liver diseases.
- Market Ocaliva for the treatment of primary biliary cholangitis (PBC).
- Develop Ocaliva for the treatment of nonalcoholic steatohepatitis (NASH).
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Seek regulatory approvals from agencies like the FDA and EMA.
- Market products through an internal commercial organization and third-party distributors.
- Engage in research and development to discover new therapies for liver diseases.
How Does ICPT Make Money?
- Develop and commercialize proprietary pharmaceutical products.
- Generate revenue through the sale of Ocaliva for PBC treatment.
- Invest in research and development to expand the product pipeline.
- Establish partnerships and collaborations to enhance product development and commercialization.
What Industry Does ICPT Operate In?
Intercept Pharmaceuticals operates within the biotechnology industry, which is characterized by high innovation, intense competition, and significant regulatory oversight. The market for liver disease therapeutics is growing, driven by the increasing prevalence of conditions like NASH and PBC. Intercept's focus on non-viral liver diseases positions it within a specialized segment of the broader pharmaceutical market. The company faces competition from larger pharmaceutical companies and other biotechnology firms developing treatments for similar indications. The biotechnology industry is subject to market trends such as advances in drug delivery technologies, personalized medicine, and gene therapy.
Who Are ICPT's Key Customers?
- Patients with primary biliary cholangitis (PBC).
- Patients with nonalcoholic steatohepatitis (NASH).
- Hospitals and clinics that treat liver diseases.
- Physicians who prescribe medications for liver conditions.
Company Profile
Intercept Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Jerome B. Durso. ICPT has traded publicly since 2012.
Intercept Pharmaceuticals, Inc. (ICPT) Valuation Context
Valued at $794.69M, ICPT is classified as a small-cap stock. Relative to its peer group, ICPT's quantitative score of 51/100 is below the peer average of 83/100.
P/E 5.6Key Financial Metrics
Return on assets is 20.8%, showing how much profit it generates from its asset base. ICPT trades at a trailing price-to-earnings ratio of 5.58, below the Healthcare sector average of ~23x. Its free cash flow yield is -3.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 17.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Intercept Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.96 places it in the distress zone, a signal of elevated financial risk.
ICPT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Established product (Ocaliva) with regulatory approval for PBC.
- Strong gross margin (99.7%).
- Focus on a specialized area of liver diseases.
- Experienced management team.
Bear Case
- Reliance on a single product (Ocaliva) for revenue.
- Potential competition from other companies developing NASH therapies.
- Regulatory risks associated with drug development and approval.
- Limited geographic presence compared to larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ICPT Latest News
No recent news available for ICPT.
ICPT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ICPT.
Price Targets
Wall Street price target analysis for ICPT.
ICPT MoonshotScore
What does this score mean?
The MoonshotScore rates ICPT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jerome B. Durso
Chief Executive Officer
Jerome B. Durso serves as the Chief Executive Officer of Intercept Pharmaceuticals, bringing extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Intercept, Durso held leadership positions at various pharmaceutical companies, including roles in commercial operations, marketing, and business development. His career spans several decades, with a focus on building and scaling pharmaceutical businesses. Durso's expertise includes strategic planning, product launches, and market access strategies. He is responsible for overseeing Intercept's overall strategy and operations.
Track Record: Since assuming the role of CEO, Jerome B. Durso has focused on driving the commercial success of Ocaliva and advancing the company's pipeline of drug candidates. Key achievements under his leadership include expanding Ocaliva's market reach and progressing the development of Ocaliva for NASH. Durso has also overseen strategic initiatives to strengthen Intercept's financial position and enhance its operational efficiency. His leadership has been instrumental in navigating the challenges and opportunities in the liver disease therapeutics market.
Common Questions About ICPT (Healthcare)
What does Intercept Pharmaceuticals, Inc. do?
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for progressive non-viral liver diseases. The company's primary product, Ocaliva, is approved for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Intercept is also developing Ocaliva for the treatment of nonalcoholic steatohepatitis (NASH), a prevalent and progressive liver condition. In addition to Ocaliva, Intercept has a pipeline of other product candidates in various stages of clinical and preclinical development, targeting different mechanisms of action to address a range of liver diseases. The company markets its products through its own commercial organization and through third-party distributors, primarily in the United States, Europe, and Canada.
What do analysts say about ICPT stock?
Analyst coverage of Intercept Pharmaceuticals, Inc. typically focuses on the company's prospects in the NASH market and the continued performance of Ocaliva in treating PBC. Key valuation metrics include revenue growth, profitability, and pipeline potential. Analyst consensus generally reflects a cautious optimism, with expectations for moderate growth driven by Ocaliva sales and potential approval for NASH. However, analysts also highlight the risks associated with clinical trial outcomes, regulatory approvals, and competition from other companies developing NASH therapies. Analyst ratings and price targets vary depending on individual assessments of these factors.
What are the main risks for ICPT?
Intercept Pharmaceuticals, Inc. faces several key risks, including clinical trial risk, regulatory risk, and competition risk. Clinical trial risk relates to the potential for unfavorable outcomes in clinical trials for NASH or other indications, which could delay or prevent regulatory approval. Regulatory risk involves the possibility of setbacks or delays in obtaining regulatory approval for new therapies. Competition risk stems from the presence of other companies developing treatments for liver diseases, particularly NASH, which could erode Intercept's market share. Other risks include changes in healthcare policies or reimbursement rates that could affect Ocaliva sales, as well as potential patent expiration for Ocaliva.
What are the key factors to evaluate for ICPT?
Intercept Pharmaceuticals, Inc. (ICPT) holds an AI score of 51/100 (moderate). P/E: 5.6x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ICPT data refresh on this page?
ICPT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ICPT's recent stock price performance?
Intercept Pharmaceuticals, Inc. (ICPT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established product (Ocaliva) with regulatory approval for PBC. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ICPT overvalued or undervalued right now?
Intercept Pharmaceuticals, Inc. (ICPT) trades at 5.6x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ICPT?
Before investing in Intercept Pharmaceuticals, Inc. (ICPT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.